The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and ...
Mayo Clinic researchers have discovered how aging "zombie cells" contribute to inflammation that speeds up a serious form of ...
The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...
Everyday Health on MSN
MASH: Is semaglutide right for you?
Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback